At Atelerix, we’re proud to support pioneering work that translates innovative science into real-world patient impact. A recent clinical milestone from our partners at the L V Prasad Eye Institute (LVPEI) offers a strong example of this - a two-year follow-up study demonstrating the effectiveness of limbal stromal stem cell therapy in treating superficial corneal pathologies such as scars, ulcers, and chemical burns.
What makes this study especially significant is not only the sustained visual improvement seen in patients, but also the use of Atelerix’s alginate encapsulation technology as part of the delivery process.
A Novel Approach to Cell Preservation and Delivery
The study, presented at ARVO 2025, involved transplanting ex-vivo cultivated allogeneic limbal stromal stem cells into the eyes of 20 patients with non-healing corneal damage. These cells were preserved using alginate, a natural hydrogel material developed by Atelerix to allow safe, room-temperature storage and transport of cells without compromising their viability or therapeutic potential.
This approach enabled the LVPEI team to maintain the integrity of delicate cells during transport, making them more accessible and practical for clinical use, especially in settings where cold chain infrastructure is limited or cost-prohibitive.
Key Clinical Findings After Two Years
The results speak volumes:
- Significant improvement in vision was observed in treated patients, with best-corrected visual acuity (BCVA) improving steadily over time
- By Day 720, improvements remained statistically and clinically meaningful
- No major adverse effects were reported across the cohort, with excellent tolerance and safety
- Corneal recovery was supported by imaging, showing restored transparency and structure
These outcomes build on LVPEI’s earlier Phase 1 trial data and support the case for expanding the use of alginate-preserved stem cell therapies for similar indications.
Supporting Scalable Regenerative Therapies
Atelerix’s mission is to enable the scalable and practical delivery of cell and gene therapies. Our alginate encapsulation platform is designed to protect cells during transport and storage without relying on ultra-low temperature freezers or cryopreservation, reducing cost and complexity across the supply chain.
By collaborating with leading research institutions like LVPEI, we’re helping ensure that promising therapies can reach patients more effectively, wherever they are.
Looking Ahead
We congratulate Dr Vivek Singh, Dr Sayan Basu, and the entire LVPEI team on this outstanding achievement. Their work not only advances the field of ophthalmic regenerative medicine but also demonstrates how innovation in cell preservation and delivery can drive better long-term patient outcomes.
As we look to the future, Atelerix remains committed to supporting our partners in accelerating the development and accessibility of advanced therapies, ensuring that life-changing science translates into life-improving care.
Learn How We Can Help Bring Your Therapy to Life
Whether you're developing a novel cell therapy, scaling up a regenerative medicine platform, or tackling the logistical challenges of transporting sensitive biological materials, Atelerix can help.
Our alginate-based preservation technology enables flexible, reliable, and cold–chain–free delivery of living cells, making advanced therapies more practical and accessible.
👉 Get in touch to explore how we can support your research, clinical trials, or commercial rollout.
Together, let’s unlock the full potential of cell-based innovation.
